VIP

A 28-amino-acid neuropeptide with broad vasodilatory and immunomodulatory activity, studied in sarcoidosis and pulmonary hypertension.

VIP is classified as a neuropeptide. Its current development status is: preclinical / limited clinical. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks VIP because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.